Are exosomes FDA approved, and what a 2026 warning letter makes clear

Quick summary

• There are no FDA approved exosome products. FDA has said so publicly since December 2019 and has repeated it in enforcement correspondence since.
• On August 14, 2026, FDA issued a warning letter to R3 Medical Companies over four cord derived and exosome marketed products, citing unapproved drug and unlicensed biological product violations along with serious manufacturing failures.
• The letter goes further than most. FDA questioned whether the manufacturing process would isolate exosomes at all.
• Whether a product is injected or applied topically does not change the analysis. Intended use does.
• The published evidence base is real but thin, and no study reviewed in a 2026 systematic review disclosed the regulatory status of the product it used.

Exosome products have moved from research language into treatment menus faster than the regulatory picture has settled, and the gap between the two is where practices get into trouble. This article covers what FDA has actually said, what the August 2026 warning letter to R3 Medical Companies contains, and what the published evidence supports as of now.

What exosomes are, and why the word itself is contested

Extracellular vesicles are particles released from cells, enclosed by a lipid bilayer, that cannot replicate on their own. They carry proteins, lipids and several classes of RNA, and their cargo reflects the state of the cell that released them. Products sold for skin and hair are typically derived from mesenchymal stromal cells sourced from umbilical cord tissue, adipose tissue or bone marrow.

The complication starts with the name. The International Society for Extracellular Vesicles, in its 2023 guidance on minimal information for studies of extracellular vesicles, discourages the term exosome unless endosomal origin can actually be demonstrated for that specific preparation. Its reasoning is blunt. Most separation techniques do not enrich for vesicles produced by one mechanism over another, and there are no universal molecular markers that distinguish exosomes from other vesicle subtypes.

The same guidance notes that some commercial kits described as exosome isolation kits rely on polymer precipitation and do not strictly isolate vesicles at all, much less a specific subtype. Size is operational rather than definitional. Small vesicles are often described as under 200 nanometers, but the measured diameter depends on the method used to measure it.

That matters for a practical reason. When a label says exosomes, there is often no published characterization behind the word.

Why no exosome product is FDA approved

The regulatory category most people assume does not apply

Human cells, tissues, and cellular and tissue based products can be regulated under section 361 of the Public Health Service Act, which does not require premarket approval, but only if they meet all four criteria in 21 CFR 1271.10(a). They must be minimally manipulated, intended for homologous use only, not combined with another article beyond narrow exceptions, and either produce no systemic effect and not depend on the metabolic activity of living cells, or fall into a short list of autologous and related uses.

Exosome products usually do not reach that test, because they are excluded one step earlier. The definition of an HCT/P in 21 CFR 1271.3(d) excludes secreted or extracted human products. Exosomes are vesicles secreted by cells. FDA has invoked that exclusion directly in enforcement correspondence, including its 2023 letter to Kimera Labs.

What is left once the exception is gone

The product then defaults to being a drug under section 201(g) of the Federal Food, Drug, and Cosmetic Act and a biological product under section 351(i) of the Public Health Service Act. FDA has stated the general position plainly: exosomes for clinical use in humans are regulated as drugs and biological products and are subject to premarket review and approval requirements.

In practice that means a biologics license is required to market one, and an investigational new drug application is required to study one in people. No exosome product holds either as a marketed product.

What the August 2026 warning letter actually says

FDA inspected two co located facilities in Scottsdale, Arizona, Bello Bio and Regen Suppliers, between November 17 and December 16, 2025. The warning letter that followed on August 14, 2026 was addressed to the chief executive of R3 Medical Companies, which FDA identified as the parent of both, along with two other entities at the same address.

The products named include four marketed by Regen and three by Bello, derived from umbilical cord tissue and umbilical cord blood, several of them sold as exosome products. The marketing quoted in the letter is what places it squarely inside aesthetics. One promotional line reads, in FDA’s quotation, that for procedures involving IVs, joints, soft tissue, hair, facial or sexual rejuvenation, the product represents the most cost effective and safe option. Other quoted claims describe collagenesis, anti scar and pro angiogenesis effects, cartilage repair and penetration of the blood brain barrier.

The finding that has no precedent in most letters

In a footnote, FDA observed that the products are marketed as exosome products, but that the manufacturing process does not appear would isolate exosomes. The phrasing is awkward and it is FDA’s own. Read alongside the vesicle field’s position on nomenclature, the regulator and the scientific society end up making the same objection from opposite directions.

The statutory citations

FDA cited the products as unapproved new drugs under section 505(a) of the FD&C Act and as unlicensed biological products under section 351(a)(1) of the PHS Act. It found the HCT/P criteria unmet because the products are not intended solely to perform the same basic function in the recipient as in the donor, and are instead intended for conditions such as arthritis and inflammation. Introducing them into interstate commerce is prohibited under section 301(d).

The manufacturing findings

The current good manufacturing practice observations are the part a practice should read closely, because they describe products administered to patients.

Manufacturing findings cited in the August 2026 warning letter

Regulation	What FDA found
21 CFR 211.113(b)	The aseptic processes used to manufacture the umbilical cord derived products were not validated.
21 CFR 211.160(b)	Samples were frozen and thawed before sterility testing, which can compromise microbial content and mask contamination present before freezing.
21 CFR 211.42(c)(10)(v)	Cleaning and disinfection of the biological safety cabinet where products are exposed during aseptic processing were not validated.
21 CFR 211.166(a)	A 24 month expiration date was assigned without supporting stability testing data.
21 CFR 211.22(d)	Quality unit responsibilities were not established in writing.

FDA gave fifteen working days to respond and closed by stating that failure to address the matters adequately may result in action without further notice, including seizure or injunction. One point deserves care in how it is repeated. This letter describes no adverse events. It is an unapproved product and manufacturing quality action, not an injury action, and it should not be characterized as one.

This was not the first action, or the first warning

FDA issued a public safety notification on exosome products in December 2019, stating that there are currently no FDA approved exosome products and citing multiple reports of serious adverse events in patients in Nebraska treated with unapproved products marketed as containing exosomes. The Nebraska state health advisory issued the same month described a product derived from cesarean section placentas and reported bacteremias caused by E. coli, Enterobacter cloacae and polymicrobial agents. Neither document gives a patient count, and no peer reviewed publication of that cluster appears to exist, so the size of it should not be stated.

Enforcement has continued. FDA issued a warning letter to Kimera Labs in September 2023 that included a positive sterility result on a specific product lot. It issued an untitled letter to Exocel Bio in May 2024, a warning letter to Platinum Biologics in August 2025 over two exosome products, and a warning letter to Dynamic Stem Cell Therapy in February 2026.

Topical or injected, the analysis does not change

The most common assumption in practice is that applying an exosome serum to skin after a procedure sits outside the regulatory question, while injecting it does not. The Exocel Bio letter undercuts that. FDA noted that according to the materials it reviewed, the products are used for injection or topical use, and quoted marketing describing topical application. It then reached the same conclusion it reaches for injected products. Based on those intended uses, the products are drugs and biological products, and marketing one lawfully requires a biologics license.

Two honest limits belong here. FDA has not published a statement that expressly distinguishes topical from injected exosome products, and its enforcement letters do not address post microneedling or post laser application specifically. Health Canada opened a consultation in August 2025 on exactly this classification question, with cosmetic status turning in part on the absence of percutaneous absorption, which would exclude anything delivered by microneedling or injection. FDA has not addressed the question in the same direct way.

What the published evidence actually supports

A 2026 systematic review and meta analysis of human clinical trials in aesthetic medicine, published in the Aesthetic Surgery Journal, pooled 39 studies, 26 in skin and 13 in hair. It reported a 20.2 percent pooled reduction in facial wrinkles, with a 95 percent confidence interval of 15.3 to 25.2, a 23.6 percent increase in hair density and an 18.0 percent increase in hair thickness. The authors state that heterogeneity and nonstandardized protocols limit generalizability, and the risk of bias tool they applied could only be applied to the randomized subset.

A separate 2026 systematic review in Dermatology Practical and Conceptual is more revealing about the shape of the literature. It included 21 articles, of which nine were clinical studies and exactly one was a randomized controlled trial. It found no serious adverse events reported across the included studies, and called for standardized trials with larger cohorts and longer follow up.

A 2026 systematic review of microneedling combined with exosomes covered 8 studies and 171 patients in total, mostly split face trials and case series, with no follow up beyond six months. Its most useful finding for a practice is not an efficacy number. The regulatory status of the externally sourced exosome products was undisclosed across all relevant studies.

Documented harm from injected preparations

Published harm exists and is specific. A 2025 case series in the Journal of Cosmetic Dermatology described four adult women who received intradermal injection of unregulated exosome formulations in a nonclinical setting. They developed persistent erythema, nodules, granulomatous inflammation and scarring. Treatment included systemic and intralesional corticosteroids, laser and surgical removal. Outcomes varied, and all four had incomplete resolution with residual scarring.

A 2024 case report in the same journal described skin necrosis after intradermal injection of a lyophilized exosome preparation, with biopsy showing necrotic keratinocytes, leukocytoclastic vasculitis and eccrine necrosis. A rechallenge with residual product on the upper arm reproduced the lesions.

These reports involve products used through unapproved routes, which is the point rather than a caveat.

What to check before a product goes on a treatment menu

The questions worth asking are short and answerable. Does the product hold a biologics license, and if the answer is that none is needed, ask why. Is there an active investigational new drug application. What exactly does the labeling and the promotional material claim, since claims are what drive classification, not the route of administration. Is there characterization data showing what is in the vial, given that FDA has now questioned whether an exosome labeled product contained exosomes. Is there sterility validation and stability data supporting the expiration date on the label. And has the manufacturer received FDA correspondence, which is public and searchable.

Everything downstream of those questions, including who may administer a given product, remains subject to state regulations and to the scope of practice of the licensed practitioners involved, which varies by state.

Sources and references

• U.S. Food and Drug Administration. Warning letter to R3 Medical Companies, August 14, 2026. Center for Biologics Evaluation and Research.
• U.S. Food and Drug Administration. Public safety notification on exosome products. Center for Biologics Evaluation and Research.
• International Society for Extracellular Vesicles. Minimal information for studies of extracellular vesicles, MISEV2023. Journal of Extracellular Vesicles.

If there are topics you would like to see covered next, write to us at editorial@upsthetics.com.

This article is provided for educational purposes only. It does not constitute medical, legal or professional advice, and it is not a substitute for guidance from qualified counsel or a licensed clinician.